Loading...
•
Dec 31, 2025
Sarepta Q4 2025 Earnings Report
Sarepta Q4 2025 Earnings Report was released, showing a decrease in total revenue and a net loss for the quarter.
Key Takeaways
Sarepta reported a challenging fourth quarter with total revenue declining 33% year-over-year to $442.9 million, primarily due to the suspension of ELEVIDYS shipments to non-ambulatory patients in the U.S. Despite the quarterly loss, the company strengthened its capital structure through debt refinancing and expects to be profitable and cash-flow positive in 2026.
Total revenue for Q4 2025 was $442.9 million, a 33% decrease compared to Q4 2024.
ELEVIDYS net product revenue fell significantly to $110.4 million following the decision to suspend shipments to non-ambulatory patients.
The company successfully refinanced $291.4 million of 2027 convertible notes into 2030 notes, reducing near-term debt overhang.
Sarepta ended 2025 with $953.8 million in cash, cash equivalents, restricted cash, and investments.
Revenue by Segment
Forward Guidance
Sarepta anticipates remaining profitable and cash-flow positive in 2026, supported by a streamlined cost structure and the potential for ELEVIDYS growth.
Positive Outlook
- Expectation to be profitable and cash-flow positive in 2026.
- Robust cash balance of nearly $1.0 billion at year-end.
- No significant debt overhang following 2027 note refinancing.
- Launch of ELEVIDYS in Japan by partner Chugai.
- Advancing siRNA pipeline with multiple clinical readouts ahead.
Challenges Ahead
- Suspension of ELEVIDYS shipments to non-ambulatory patients in the U.S.
- Updated ELEVIDYS label includes a boxed warning for serious liver injury.
- Significant inventory valuation reserves recorded in Q4 2025.
- Increased interest expense due to higher rates on 2030 notes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...